humira

AbbVie, Eisai, and EA Pharma Launch “Humira Support Tool Ordering Service for Patients”

TOKYO, Sep 13, 2021 – (JCN Newswire via SEAPRWire.com) – AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd. announced today that, on September 13, 2021, the companies launched “Humira Support Tool Ordering Service for Patients” an initiative intended to improve patients’ adherence to Humira therapy. “Humira Support Tool Ordering Service for Patients” is... » read more

AbbVie and Eisai Announce an approval for additional indication of HUMIRA

TOKYO, Nov 27, 2020 – (JCN Newswire) – AbbVie GK and Eisai Co., Ltd. today announced an approval of additional indication of HUMIRA (generic name: adalimumab [recombinant], hereafter “HUMIRA”), a fully human anti-TNFalpha monoclonal antibody, for the treatment of pyoderma gangrenosum (hereafter “PG”). HUMIRA was granted orphan drug designation for the treatment of PG in... » read more